“We applaud the members of the Senate Judiciary Committee for voting the CREATES Act out of committee and advancing this bipartisan legislation one step closer to becoming law. “The CREATES Act will put an end to anticompetitive practices used by some drug manufacturers to thwart generic competition and artificially keep drug prices high. It is […]
“When the manufacturer-set price of a drug starts out high, the price of that drug when it reaches patients will inevitably end up high. No amount of finger pointing can change the fact that the root cause of this crisis is out-of-control list and launch prices set by Big Pharma. “Fundamentally, the problem is the […]
46 organizations today applauded Chairman Chuck Grassley and Ranking Member Dianne Feinstein for scheduling a markup of the bipartisan, bicameral Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act. Senators Grassley, Feinstein, Leahy, and their 24 bipartisan Senate colleagues who have co-sponsored the CREATES Act deserve credit for their leadership on the critical issue […]
Today, the Office of the Inspector General at the Department of Health and Human Services (OIG) released a report entitled, “Increases in Reimbursement for Brand-Name Drugs in Part D.” The OIG found that, over the course of five years, after taking rebates and discounts into account, spending by Medicare Part D on brand-name medications rose by […]
The Campaign for Sustainable Rx Pricing released the following statement attributable to CSRxP spokesman Will Holley: “Today’s FDA guidance is a step in the right direction towards our common goal of lowering out-of-control drug prices. When generic and biosimilar competition is thwarted by these abusive tactics, brand-name manufacturers, who alone control the price of their […]
The Campaign for Sustainable Rx Pricing released the following statement attributable to CSRxP spokesman Will Holley: “We applaud the Administration’s focus on out-of-control prescription drug prices and, in particular, the anticompetitive tactics used by brand-name manufacturers to keep drug prices artificially high. In publishing this database, the FDA will shine a light on one of […]
The Campaign for Sustainable Rx Pricing released the following statement attributable to CSRxP Executive Director Lauren Aronson: “We applaud the President for his focus on this crisis that has hurt far too many American families. In this debate, there is one indisputable fact: drug manufacturers alone set the price of drugs, and the problem is […]
March 8, 2018 Contact: [email protected] ( 202) 286-4682 The Campaign for Sustainable Rx Pricing (CSRxP) launched an advertising campaign today calling on Congress to pass the CREATES Act as part of the omnibus spending package this month. The bill, which the CBO projects would save taxpayers $3.8 billion, targets Big Pharma’s abuse of Risk Evaluation […]
The Campaign for Sustainable Rx Pricing released the following statement attributable to spokesman Will Holley on the nomination of Alex Azar: “Out-of-control prescription drug prices are the number 1 domestic policy concern for American voters. And, while the FDA is working hard to address anticompetitive abuses by branded manufacturers, there remains much to be done […]
“We are excited to join CSRxP and be a part of the coalition to achieve reasonable prescription drug prices,” says Jody Hatcher, president, sourcing and collaboration services at Vizient. “Our health care members are facing enormous financial and clinical pressures associated with pharmaceuticals.